Kelly Lawrence W & Associates Inc. CA Takes $31,000 Position in Becton, Dickinson and Company $BDX

Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 135 shares of the medical instruments supplier’s stock, valued at approximately $31,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Compound Planning Inc. grew its holdings in Becton, Dickinson and Company by 33.3% during the 1st quarter. Compound Planning Inc. now owns 1,408 shares of the medical instruments supplier’s stock valued at $323,000 after purchasing an additional 352 shares during the last quarter. 1832 Asset Management L.P. grew its holdings in Becton, Dickinson and Company by 10.0% during the 1st quarter. 1832 Asset Management L.P. now owns 305,950 shares of the medical instruments supplier’s stock valued at $70,081,000 after purchasing an additional 27,760 shares during the last quarter. Monetary Management Group Inc. grew its holdings in Becton, Dickinson and Company by 40.0% during the 1st quarter. Monetary Management Group Inc. now owns 350 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 100 shares during the last quarter. Norinchukin Bank The grew its holdings in Becton, Dickinson and Company by 12.2% during the 1st quarter. Norinchukin Bank The now owns 12,687 shares of the medical instruments supplier’s stock valued at $2,906,000 after purchasing an additional 1,380 shares during the last quarter. Finally, Clarkston Capital Partners LLC grew its holdings in Becton, Dickinson and Company by 2.4% during the 1st quarter. Clarkston Capital Partners LLC now owns 87,664 shares of the medical instruments supplier’s stock valued at $20,080,000 after purchasing an additional 2,017 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BDX has been the topic of several analyst reports. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Raymond James Financial downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Friday, May 2nd. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price target for the company. in a research report on Friday, May 2nd. Finally, Bank of America cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target for the company. in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $211.44.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares of the company’s stock, valued at approximately $4,450,398.90. This represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,214 shares of company stock valued at $579,206. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.4%

NYSE:BDX opened at $196.4380 on Friday. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The firm has a 50 day moving average of $180.10 and a 200 day moving average of $195.89. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $56.31 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 1.49 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the prior year, the company posted $3.50 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.